182 related articles for article (PubMed ID: 33450274)
1. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
2. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Welzel B; Schmidt R; Kirchhoff L; Gramer M; Löscher W
Epilepsy Behav; 2023 Feb; 139():109057. PubMed ID: 36586153
[TBL] [Abstract][Full Text] [Related]
3. The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Hampel P; Römermann K; Gramer M; Löscher W
Epilepsy Behav; 2021 Jan; 114(Pt A):107616. PubMed ID: 33279441
[TBL] [Abstract][Full Text] [Related]
4. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
5. The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.
Erker T; Brandt C; Töllner K; Schreppel P; Twele F; Schidlitzki A; Löscher W
Epilepsia; 2016 May; 57(5):698-705. PubMed ID: 26921222
[TBL] [Abstract][Full Text] [Related]
6. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
Hampel P; Römermann K; MacAulay N; Löscher W
Sci Rep; 2018 Jun; 8(1):9877. PubMed ID: 29959396
[TBL] [Abstract][Full Text] [Related]
7. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.
Cleary RT; Sun H; Huynh T; Manning SM; Li Y; Rotenberg A; Talos DM; Kahle KT; Jackson M; Rakhade SN; Berry G; Jensen FE
PLoS One; 2013; 8(3):e57148. PubMed ID: 23536761
[TBL] [Abstract][Full Text] [Related]
8. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
Kahle KT; Staley KJ
Neurosurg Focus; 2008 Sep; 25(3):E22. PubMed ID: 18759624
[TBL] [Abstract][Full Text] [Related]
9. CNS pharmacology of NKCC1 inhibitors.
Löscher W; Kaila K
Neuropharmacology; 2022 Mar; 205():108910. PubMed ID: 34883135
[TBL] [Abstract][Full Text] [Related]
10. A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Gharaylou Z; Tafakhori A; Agah E; Aghamollaii V; Kebriaeezadeh A; Hadjighassem M
CNS Drugs; 2019 Mar; 33(3):283-291. PubMed ID: 30784026
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures.
Wang S; Zhang XQ; Song CG; Xiao T; Zhao M; Zhu G; Zhao CS
Neuroscience; 2015 Feb; 286():203-15. PubMed ID: 25463517
[TBL] [Abstract][Full Text] [Related]
12. NKCC1 transporter facilitates seizures in the developing brain.
Dzhala VI; Talos DM; Sdrulla DA; Brumback AC; Mathews GC; Benke TA; Delpire E; Jensen FE; Staley KJ
Nat Med; 2005 Nov; 11(11):1205-13. PubMed ID: 16227993
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
Brandt C; Nozadze M; Heuchert N; Rattka M; Löscher W
J Neurosci; 2010 Jun; 30(25):8602-12. PubMed ID: 20573906
[TBL] [Abstract][Full Text] [Related]
14. A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Johne M; Käufer C; Römermann K; Gailus B; Gericke B; Löscher W
Epilepsia; 2021 Jun; 62(6):1460-1471. PubMed ID: 33955541
[TBL] [Abstract][Full Text] [Related]
15. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
Dzhala VI; Brumback AC; Staley KJ
Ann Neurol; 2008 Feb; 63(2):222-35. PubMed ID: 17918265
[TBL] [Abstract][Full Text] [Related]
16. Astrocytic NKCC1 inhibits seizures by buffering Cl
Nguyen TD; Ishibashi M; Sinha AS; Watanabe M; Kato D; Horiuchi H; Wake H; Fukuda A
Epilepsia; 2023 Dec; 64(12):3389-3403. PubMed ID: 37779224
[TBL] [Abstract][Full Text] [Related]
17. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
Lykke K; Töllner K; Feit PW; Erker T; MacAulay N; Löscher W
Epilepsy Behav; 2016 Jun; 59():42-9. PubMed ID: 27088517
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Auer T; Schreppel P; Erker T; Schwarzer C
Neuropharmacology; 2020 Jan; 162():107754. PubMed ID: 31476353
[TBL] [Abstract][Full Text] [Related]
19. NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility.
Wang F; Wang X; Shapiro LA; Cotrina ML; Liu W; Wang EW; Gu S; Wang W; He X; Nedergaard M; Huang JH
Brain Struct Funct; 2017 Apr; 222(3):1543-1556. PubMed ID: 27586142
[TBL] [Abstract][Full Text] [Related]
20. Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies.
Rao S; Farhat A; Rakshasbhuvankar A; Athikarisamy S; Ghosh S; Nagarajan L
Seizure; 2023 Oct; 111():206-214. PubMed ID: 37690372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
